Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556847 | 0.80 | PIK3CA (0.47) | PIK3CACYP3A4PIK3CGPIK3CBDYRK1A | |
| SCHEMBL3146231 | 0.79 | PIK3CA (1.00) | PIK3CACYP3A4PIK3CGPIK3CDPIK3CB | |
| SCHEMBL3146053 | 0.78 | PIK3CA (0.70) | PIK3CACYP3A4PIK3CGPIK3CDPIK3CB | |
| SCHEMBL1650380 | 0.78 | PIK3CA (0.63) | PIK3CACYP3A4PIK3CGPI4KBDYRK1A | |
| SCHEMBL3131463 | 0.78 | PIK3CA (0.72) | PIK3CACYP3A4PIK3CGPIK3CDPIK3CB | |
| SCHEMBL3131497 | 0.78 | PIK3CA (0.72) | PIK3CACYP3A4PIK3CGPIK3CDPIK3CB | |
| SCHEMBL3142152 | 0.78 | PIK3CA (0.72) | PIK3CACYP3A4PIK3CGPIK3CDPIK3CB | |
| SCHEMBL3150659 | 0.74 | PIK3CA (0.70) | PIK3CACYP3A4PIK3CGPIK3CDPIK3CB | |
| SCHEMBL1649960 | 0.71 | PIK3CA (0.66) | PIK3CAPIK3CGPIK3CDPIK3CBPIK3C3 | |
| SCHEMBL7994975 | 0.71 | PIK3CA (0.45) | PIK3CAPIK3CGPIK3CDPIK3CBPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | claimed |
| EP-2311842-A2 | PI3K/M TOR inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | claimed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2311842-A2 | PI3K/M TOR inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010008847-A2 | PI3K/M TOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178070-A1 | PI3K/mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885CYP3A4 1083/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.